All In Biotech

Drug Trial Radar · NCT06879782

Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study on the Efficacy and Safety of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease.

Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 820 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

820

Planned (sponsor's estimate)

Start

Mar 28, 2024

Primary completion

Mar 28, 2026

Study completion Sep 28, 2026

Sponsor

Sponsor type
Industry
Collaborators
Beijing Tongren Hospital
First posted
Mar 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of Lifitegrast Ophthalmic Solution.

Conditions

  • Dry Eye Disease (DED)

Interventions

  • Drug placeboDrug

    Instill one drop of the eye solution in each eye, twice a day (morning and evening, approximately 12 hours apart), for a treatment period of 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Inferior Corneal Fluorescein Staining ScoreTime frame: After 84 days of treatment
  2. Eye Dryness ScoreTime frame: After 84 days of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.